The evolving world of HER2-low in advanced breast cancer: HER2-low (HER2 IHC 1+ or 2+ with negative ISH) is an emerging biomarker that can help identify patients with metastatic breast cancer eligible for ENHERTU® (fam-trastuzumab deruxtecan-nxki). This therapy is associated with significant improvement in survival outcomes for patients. The Labcorp Oncology team, Drs. Heidi Ko and Jonathan Klein, hosted a webinar discussing updates to our HER2 test offering and details about the practice-changing results for patients with HER2-low metastatic breast cancer.